CA2435573A1 — Alkyl aryl polyether alcohol polymers for improvement of nasal breathing

USPTO Abstract

A method and composition for treatment and prophylaxis of snoring, sleep apn ea or sudden infant death syndrome and for improvement of nasal breathing in mammals by nasal and/or pharyngeal administration of tyloxapol or a related alkylaryl polyether alcohol polymer. A spray, liquid or solid composition comprising from about 0.01 to about 20 % (w/v), equivalent to about 100 .mu.g/ml to about 200 mg/ml, or tyloxapol or another alkylaryl polyether alcohol polymer alone or in admixture with pharmaceutically acceptable excipients and additives. The composition is administered as a spray, liquid , liquid drops, lozenges or powder suitable for nasal and/or pharyngeal application.